According to IMS, the market research firm, hospitals purchased $440,000 of Recothrom during June. In a research report, Kevin DeGeeter, an analyst at Oppenheimer & Co., said he forecast sales would be $750,000 for the month. DeGeeter said that stockpiling by wholesalers (which is not counted in the IMS numbers) should "largely offset weak user demand" by hospitals. He expects second-quarter Recothrom sales to be only slightly below his initial estimate of $3.3 million.
Orthovita will also hold a conference call on Thursday, August 7, 2008, at 8:30 a.m. Eastern Time, to review and discuss its financial results for the second quarter 2008. Antony Koblish, President and Chief Executive Officer, and Albert J. Pavucek, Jr., Chief Financial Officer of Orthovita, will host the call.